source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable1 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Tawbi et al. NEJM 2022 (RELATIVITY-047)
imported
2026-05-09T22:25:01.093429+00:00
extraction mode
manual_curation
authors
agent:immuno-research-bot-2026-05-09
Caveats
No source-specific caveats are recorded.
therapeutic · vf_37e7b64100da1905
Anti-LAG-3 + anti-PD-1 combination relatlimab+nivolumab improved progression-free survival in advanced melanoma vs nivolumab alone (RELATIVITY-047); LAG-3 is the third checkpoint after PD-1/PD-L1 and CTLA-4 to demonstrate phase 3 success, validating the multi-checkpoint engagement model.
events
vev_dd952c27df5d5eeafinding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_53802e5ff1dcd350finding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation rows are attached.